Childhood nephrotic syndrome-current and future therapies

Nature Reviews Nephrology

Volumn 8, Issue 8, 2012, Pages 445-458

  Greenbaum, Larry A ^a   Benndorf, Rainer ^b   Smoyer, William E ^b  

^a EMORY UNIVERSITY   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADALIMUMAB; CORTICOSTEROID; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; GALACTOSE; GLUCOCORTICOID; METHYLPREDNISOLONE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIOGLITAZONE; RITUXIMAB; ROSIGLITAZONE; TACROLIMUS;

CELL FUNCTION; CELL STRUCTURE; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DRUG EFFICACY; GENE TARGETING; GINGIVA HYPERPLASIA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; NEPHROTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; PLASMAPHERESIS; PODOCYTE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; T LYMPHOCYTE; TREATMENT RESPONSE; UNFOLDED PROTEIN RESPONSE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; CYCLOPHOSPHAMIDE; CYCLOSPORINE; ENZYME INHIBITORS; GALACTOSE; GLUCOCORTICOIDS; HOMEOSTASIS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-13; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; MYCOPHENOLIC ACID; NEPHROTIC SYNDROME; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLASMAPHERESIS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, NOTCH; RIBONUCLEOSIDES; SIGNAL TRANSDUCTION; TACROLIMUS; THIAZOLIDINEDIONES; UNFOLDED PROTEIN RESPONSE;

EID: 84864334538     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.115     Document Type: Review

References (201)

1. Arneil, G. C. The nephrotic syndrome. Pediatr. Clin. North Am. 18, 547-559 (1971).
2. Cameron, J. S. in The Nephrotic Syndrome (eds Cameron, J. S., Glassock, R. J. & Whelton, A.) 3-56 (Marcel Dekker, Inc., New York, 1988).
3. Arneil, G. C. & Lam, C. N. Long-term assessment of steroid therapy in childhood nephrosis. Lancet 2, 819-821 (1966).
4. Minimal change nephrotic syndrome in children: Deaths during the first 5 to 15 years observation. Report of the International Study of Kidney Disease in Children. Pediatrics 73, 497-501 (1984).
5. Chavers, B. M., Li, S., Collins, A. J. & Herzog, C. A. Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int. 62, 648-653 (2002). (Pubitemid 34784616)
6. Benoit, G., Machuca, E. & Antignac, C. Hereditary nephrotic syndrome: A systematic approach for genetic testing and a review of associated podocyte gene mutations. Pediatr. Nephrol. 25, 1621-1632 (2010).
7. Machuca, E., Benoit, G. & Antignac, C. Genetics of nephrotic syndrome: Connecting molecular genetics to podocyte physiology. Hum. Mol. Genet. 18, R185-R194 (2009).
8. Lowik, M. M., Groenen, P. J., Levtchenko, E. N., Monnens, L. A. & Van Den Heuvel, L. P. Molecular genetic analysis of podocyte genes in focal segmental glomerulosclerosis-a review. European Journal of Pediatrics, 168 (11), 2009,pages:1291-1304
9. Savin, V. J. et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N. Engl. J. Med. 334, 878-883 (1996). (Pubitemid 26107345)
10. Wei, C. et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 17, 952-960 (2011).
11. Hinkes, B. et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat. Genet. 38, 1397-1405 (2006). (Pubitemid 44837561)
12. Ozaltin, F. et al. Disruption of PTPRO causes childhood-onset nephrotic syndrome. Am. J. Hum. Genet. 89, 139-147 (2011).
13. Wei, C. & Reiser, J. Minimal change disease as a modifiable podocyte paracrine disorder. Nephrol. Dial. Transplant. 26, 1776-1777 (2011).
14. Schonenberger, E., Ehrich, J. H., Haller, H. & Schiffer, M. The podocyte as a direct target of immunosuppressive agents. Nephrol. Dial. Transplant. 26, 18-24 (2011).
15. Churg, J., Habib, R. & White, R. H. Pathology of the nephrotic syndrome in children: A report for the International Study of Kidney Disease in Children. Lancet 760, 1299-1302 (1970).
16. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J. Pediatr. 98, 561-564 (1981).
17. Primary nephrotic syndrome in children: Clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. Kidney Int. 20, 765-771 (1981).
18. Eddy, A. A. & Symons, J. M. Nephrotic syndrome in childhood. Lancet 362, 629-639 (2003). (Pubitemid 37013306)
19. Rydel, J. J., Korbet, S. M., Borok, R. Z. & Sxhwartz, M. M. Focal segmental glomerular sclerosis in adults: Presentation, course, and response to treatment. Am. J. Kidney Dis. 25, 534-542 (1995).
20. Chun, M. J., Korbet, S. M., Schwartz, M. M. & Lewis, E. J. Focal segmental glomerulosclerosis in nephrotic adults: Presentation, prognosis, and response to therapy of the histologic variants. J. Am. Soc. Nephrol. 15, 2169-2177 (2004). (Pubitemid 39031355)
21. Hodson, E. M., Willis, N. S. & Craig, J. C. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database of Systematic Reviews, Issue 4. Article No.: CD001533.doi:10.1002/14651858.CD001533.pub4 (2007). (Pubitemid 351805200)
22. Saadeh, S. A. et al. Weight or body surface area dosing of steroids in nephrotic syndrome: Is there an outcome difference? Pediatr. Nephrol. 26, 2167-2171 (2011).
23. Ransom, R. F., Lam, N. G., Hallett, M. A., Atkinson, S. J. & Smoyer, W. E. Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney Int. 68, 2473-2483 (2005). (Pubitemid 43250994)
24. Murnaghan, K., Vasmant, D. & Bensman, A. Pulse methylprednisolone therapy in severe idiopathic childhood nephrotic syndrome. Acta Paediatr. Scand. 73, 733-739 (1984). (Pubitemid 15209673)
25. Hari, P., Bagga, A. & Mantan, M. Short term efficacy of intravenous dexamethasone and methylprednisolone therapy in steroid resistant nephrotic syndrome. Indian Pediatr. 41, 993-1000 (2004). (Pubitemid 39425311)
26. Mori, K., Honda, M. & Ikeda, M. Efficacy of methylprednisolone pulse therapy in steroid-resistant nephrotic syndrome. Pediatr. Nephrol. 19, 1232-1236 (2004). (Pubitemid 39462423)
27. Shenoy, M. et al. Intravenous methylprednisolone in idiopathic childhood nephrotic syndrome. Pediatr. Nephrol. 25, 899-903 (2010).
28. Tune, B. M. et al. Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: A long-term follow-up. Clin. Nephrol. 43, 84-88 (1995).
29. Tune, B. M. & Mendoza, S. A. Treatment of the idiopathic nephrotic syndrome: Regimens and outcomes in children and adults. J. Am. Soc. Nephrol. 8, 824-832 (1997). (Pubitemid 27493599)
30. Mendoza, S. A. et al. Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr. Nephrol. 4, 303-307 (1990). (Pubitemid 20252779)
31. Ehrich, J. H. et al. Steroid-resistant idiopathic childhood nephrosis: Overdiagnosed and undertreated. Nephrol. Dial. Transplant. 22, 2183-2193 (2007). (Pubitemid 47244695)
32. Vester, U., Kranz, B., Zimmermann, S. & Hoyer, P. F. Cyclophosphamide in steroid-sensitive nephrotic syndrome: Outcome and outlook. Pediatr. Nephrol. 18, 661-664 (2003). (Pubitemid 36826850)
33. Plank, C. et al. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie. Pediatr. Nephrol. 23, 1483-1493 (2008).
34. Sharda, S. V. et al. Do glutathione S transferase polymorphisms influence response to intravenous cyclophosphamide therapy in idiopathic nephrotic syndrome? Pediatr. Nephrol. 23, 2001-2006 (2008).
35. Vester, U., Kranz, B., Zimmermann, S., Buscher, R. & Hoyer, P. F. The response to cyclophosphamide in steroid-sensitive nephrotic syndrome is influenced by polymorphic expression of glutathion S transferases M1 and P1. Pediatr. Nephrol. 20, 478-481 (2005). (Pubitemid 40392622)
36. Latta, K., von Schnakenburg, C. & Ehrich, J. H. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr. Nephrol. 16, 271-282 (2001). (Pubitemid 32229852)
37. Dooley, M. A. et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 365, 1886-1895 (2011).
38. Tang, S. C. et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int. 77, 543-549 (2010).
39. Eugui, E. M., Almquist, S. J., Muller, C. D. & Allison, A. C. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion. Scand. J. Immunol. 33, 161-173 (1991).
40. Ishikawa, H. Mizoribine and mycophenolate mofetil. Curr. Med. Chem. 6, 575-597 (1999). (Pubitemid 29328002)
41. Senthil Nayagam, L. et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: A pilot study. Nephrol. Dial. Transplant. 23, 1926-1930 (2008). (Pubitemid 351768140)
42. Cattran, D. C., Wang, M. M., Appel, G., Matalon, A. & Briggs, W. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin. Nephrol. 62, 405-411 (2004). (Pubitemid 39654577)
43. Moudgil, A., Bagga, A. & Jordan, S. C. Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: Current status and future directions. Pediatr. Nephrol. 20, 1376-1381 (2005). (Pubitemid 41403409)
44. Fujinaga, S. et al. Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: Extended experience in a single center. Clin. Nephrol. 72, 268-273 (2009).
45. De Mello, V. R. et al. Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome. Pediatr. Nephrol. 25, 453-460 (2010).
46. Gargah, T. T. & Lakhoua, M. R. Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome. J. Nephrol. 24, 203-207 (2011).
47. Gipson, D. S. et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 80, 868-878 (2011).
48. Fujinaga, S. et al. Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration. Pediatr. Nephrol. 26, 479-483 (2011).
49. Tanaka, H. et al. Mizoribine pulse therapy for a pediatric patient with steroid-resistant nephrotic syndrome. Tohoku J. Exp. Med. 205, 87-91 (2005). (Pubitemid 40260058)
50. Borel, J. F. Mechanism of action of cyclosporin A and rationale for use in nephrotic syndrome. Clin. Nephrol. 35 (Suppl. 1), S23-S30 (1991).
51. Faul, C. et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 14, 931-938 (2008).
52. Lieberman, K. V. & Tejani, A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J. Am. Soc. Nephrol. 7, 56-63 (1996). (Pubitemid 26068448)
53. Cattran, D. C. et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 56, 2220-2226 (1999). (Pubitemid 30004751)
54. Niaudet, P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J. Pediatr. 125, 981-986 (1994). (Pubitemid 24379137)
55. Iijima, K. et al. Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int. 61, 1801-1805 (2002). (Pubitemid 34437934)
56. Bowman, L. J. & Brennan, D. C. The role of tacrolimus in renal transplantation. Expert Opin. Pharmacother. 9, 635-643 (2008). (Pubitemid 351425390)
57. McCauley, J. et al. Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. Nephrol. Dial. Transplant. 8, 1286-1290 (1993). (Pubitemid 23342670)
58. Gulati, S. et al. Tacrolimus: A new therapy for steroid-resistant nephrotic syndrome in children. Nephrol. Dial. Transplant. 23, 910-913 (2008). (Pubitemid 351767558)
59. Loeffler, K., Gowrishankar, M. & Yiu, V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr. Nephrol. 19, 281-287 (2004). (Pubitemid 38313011)
60. Westhoff, T. H., Schmidt, S., Zidek, W., Beige, J. & Van Der Giet, M. Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome. Clin. Nephrol. 65, 393-400 (2006). (Pubitemid 43853527)
61. Choudhry, S. et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: A randomized controlled trial. Am. J. Kidney Dis. 53, 760-769 (2009).
62. Bhimma, R., Adhikari, M., Asharam, K. & Connolly, C. Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. Am. J. Nephrol. 26, 544-551 (2006). (Pubitemid 46143876)
63. Garcia, C. D. et al. Plasmapheresis for recurrent posttransplant focal segmental glomerulosclerosis. Transplant. Proc. 38, 1904-1905 (2006). (Pubitemid 44190082)
64. Bosch, T. & Wendler, T. Extracorporeal plasma treatment in primary and recurrent focal segmental glomerular sclerosis: A review. Ther. Apher. 5, 155-160 (2001). (Pubitemid 32641173)
65. Pradhan, M., Petro, J., Palmer, J., Meyers, K. & Baluarte, H. J. Early use of plasmapheresis for recurrent post-transplant FSGS. Pediatr. Nephrol. 18, 934-938 (2003). (Pubitemid 37121629)
66. Feld, S. M. et al. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am. J. Kidney Dis. 32, 230-237 (1998).
67. Ginsburg, D. S. & Dau, P. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis. Clin. Nephrol. 48, 282-287 (1997). (Pubitemid 27496651)
68. Oliveira, L., Wang, D. & McCormick, B. B. A case report of plasmapheresis and cyclophosphamide for steroid-resistant focal segmental glomerulosclerosis: Recovery of renal function after five months on dialysis. Ther. Apher. Dial. 11, 227-231 (2007). (Pubitemid 46716165)
69. Jayne, D. Role of rituximab therapy in glomerulonephritis. J. Am. Soc. Nephrol. 21, 14-17 (2010).
70. Ruggenenti, P. et al. Rituximab for idiopathic membranous nephropathy: Who can benefit? Clin. J. Am. Soc. Nephrol. 1, 738-748 (2006).
71. Fervenza, F. C. et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 73, 117-125 (2008). (Pubitemid 350273646)
72. Fornoni, A. et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci. Transl. Med. 3, 85ra46 (2011).
73. Guigonis, V. et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: A multicentric series of 22 cases. Pediatr. Nephrol. 23, 1269-1279 (2008).
74. Prytula, A. et al. Rituximab in refractory nephrotic syndrome. Pediatr. Nephrol. 25, 461-468 (2010).
75. Gulati, A. et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: Multicentric report. Clin. J. Am. Soc. Nephrol. 5, 2207-2212 (2010).
76. Bagga, A., Sinha, A. & Moudgil, A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N. Engl. J. Med. 356, 2751-2752 (2007). (Pubitemid 47001064)
77. Kari, J. A. et al. Rituximab for refractory cases of childhood nephrotic syndrome. Pediatr. Nephrol. 26, 733-737 (2011).
78. Suri, M., Tran, K., Sharma, A. P., Filler, G. & Grimmer, J. Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab. Int. Urol. Nephrol. 40, 807-810 (2008).
79. Kurosu, N. et al. Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome. Intern. Med. 48, 1901-1904 (2009).
80. Peters, H. P., Van De Kar, N. C. & Wetzels, J. F. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: Report of four cases and review of the literature. Neth. J. Med. 66, 408-415 (2008).
81. Smith, G. C. Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome? Pediatr. Nephrol. 22, 893-898 (2007). (Pubitemid 46629628)
82. Nakayama, M. et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr. Nephrol. 23, 481-485 (2008).
83. Sharma, A. P. & Filler, G. Role of mycophenolate mofetil in remission maintenance after a successful response to rituximab. Pediatr. Nephrol. 24, 423-424 (2009).
84. Ravani, P. et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: A randomized controlled trial. Clin. J. Am. Soc. Nephrol. 6, 1308-1315 (2011).
85. Sinha, A., Bagga, A., Gulati, A. & Hari, P. Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome. Pediatr. Nephrol. 27, 235-241 (2011).
86. Sellier-Leclerc, A. L. et al. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood-follow up after CD19 recovery. Nephrol. Dial. Transplant. 27, 1083-1089 (2012).
87. Kemper, M. J. et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol. Dial. Transplant. http://dx.doi:10.1093/ndt/gfr548.
88. Iijima, K. Rituximab for childhood refractory nephrotic syndrome. Pediatr. Int. 53, 617-621 (2011).
89. Magnasco, A. Rituximab in children with resistant idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. http://dx.doi:10.1681/ASN.2011080775.
90. Sellier-Leclerc, A. L. et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr. Nephrol. 25, 1109-1115 (2010).
91. Kamei, K. et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr. Nephrol. 24, 1321-1328 (2009).
92. Ardelean, D. S. et al. Severe ulcerative colitis after rituximab therapy. Pediatrics 126, e243-e246 (2010).
93. Chan, A. C. Rituximabs new therapeutic target: The podocyte actin cytoskeleton. Sci. Transl. Med. 3, 85ps21 (2011).
94. Savin, V. J., McCarthy, E. T., Sharma, R., Charba, D. & Sharma, M. Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl. Res. 151, 288-292 (2008).
95. De Smet, E., Rioux, J. P., Ammann, H., Deziel, C. & Querin, S. FSGS permeability factor-associated nephrotic syndrome: Remission after oral galactose therapy. Nephrol. Dial. Transplant. 24, 2938-2940 (2009).
96. Kopac, M., Meglic, A. & Rus, R. R. Partial remission of resistant nephrotic syndrome after oral galactose therapy. Ther. Apher. Dial. 15, 269-272 (2011).
97. Novel therapies in resistant focal segmental glomerulosclerosis: Www.fonttrial.org (2010).
98. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrails.gov/ct2/show/NCT01113385?term=NCT01113385&rank=1 (2012).
99. Suranyi, M. G., Guasch, A., Hall, B. M. & Myers, B. D. Elevated levels of tumor necrosis factor-alpha in the nephrotic syndrome in humans. Am. J. Kidney Dis. 21, 251-259 (1993). (Pubitemid 23100335)
100. Bustos, C., Gonzalez, E., Muley, R., Alonso, J. L. & Egido, J. Increase of tumour necrosis factor alpha synthesis and gene expression in peripheral blood mononuclear cells of children with idiopathic nephrotic syndrome. Eur. J. Clin. Invest. 24, 799-805 (1994). (Pubitemid 24374775)
101. Gupta, A., Pendyala, P., Arora, P. & Sitrin, M. D. Development of the nephrotic syndrome during treatment of Crohns disease with adalimumab. J. Clin. Gastroenterol. 45, e30-e33 (2011).
102. Nowak, B., Jeka, S., Wiland, P. & Szechinski, J. Rapid and complete resolution of ascites and hydrothorax due to nephrotic syndrome caused by renal amyloidosis in a patient with juvenile chronic arthritis treated with adalimumab. Joint Bone Spine 76, 217-219 (2009).
103. Joy, M. S. et al. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am. J. Kidney Dis. 55, 50-60 (2010).
104. Michalik, L. et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 58, 726-741 (2006). (Pubitemid 44833742)
105. Ma, L. J., Marcantoni, C., Linton, M. F., Fazio, S. & Fogo, A. B. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int. 59, 1899-1910 (2001). (Pubitemid 32336806)
106. Yang, H. C., Ma, L. J., Ma, J. & Fogo, A. B. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int. 69, 1756-1764 (2006). (Pubitemid 43739202)
107. Cha, D. R. et al. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes 56, 2036-2045 (2007).
108. Sarafidis, P. A., Stafylas, P. C., Georgianos, P. I., Saratzis, A. N. & Lasaridis, A. N. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: A meta-analysis. Am. J. Kidney Dis. 55, 835-847 (2010).
109. Mao, Z. & Ong, A. C. Peroxisome proliferator-activated receptor gamma agonists in kidney disease-future promise, present fears. Nephron Clin. Pract. 112, c230-c241 (2009).
110. Kanjanabuch, T. et al. PPAR-gamma agonist protects podocytes from injury. Kidney Int. 71, 1232-1239 (2007). (Pubitemid 46884258)
111. Liu, H. F. et al. Thiazolidinedione attenuate proteinuria and glomerulosclerosis in Adriamycin-induced nephropathy rats via slit diaphragm protection. Nephrology (Carlton) 15, 75-83 (2010).
112. Agrawal, S., Guess, A. J., Benndorf, R. & Smoyer, W. E. Comparison of direct action of thiazolidinediones and glucocorticoids on renal podocytes: Protection from injury and molecular effects. Mol. Pharmacol. 80, 389-399 (2011).
113. Kawai, T. et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-β. Lab. Invest. 89, 47-58 (2009).
114. Coulthard, L. R., White, D. E., Jones, D. L., McDermott, M. F. & Burchill, S. A. p38(MAPK): Stress responses from molecular mechanisms to therapeutics. Trends Mol. Med. 15, 369-379 (2009).
115. Grande, M. T. & Lopez-Novoa, J. M. Therapeutical relevance of MAP-kinase inhibitors in renal diseases: Current knowledge and future clinical perspectives. Curr. Med. Chem. 15, 2054-2070 (2008).
116. Gaestel, M. Specificity of signaling from MAPKs to MAPKAPKs: kinases tango nuevo. Front. Biosci. 13, 6050-6059 (2008).
117. Stambe, C., Atkins, R. C., Hill, P. A. & Nikolic-Paterson, D. J. Activation and cellular localization of the p38 and JNK MAPK pathways in rat crescentic glomerulonephritis. Kidney Int. 64, 2121-2132 (2003). (Pubitemid 37449546)
118. Sheryanna, A. et al. Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glomerulonephritis and suppresses monocyte chemoattractant protein 1 but not IL 1β or IL 6. J. Am. Soc. Nephrol. 18, 1167-1179 (2007). (Pubitemid 46536903)
119. Koshikawa, M. et al. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J. Am. Soc. Nephrol. 16, 2690-2701 (2005).
120. Stambe, C., Nikolic-Paterson, D. J., Hill, P. A., Dowling, J. & Atkins, R. C. p38 Mitogen-activated protein kinase activation and cell localization in human glomerulonephritis: Correlation with renal injury. J. Am. Soc. Nephrol. 15, 326-336 (2004). (Pubitemid 38140773)
121. Polzer, K. et al. Selective p38MAPK isoform expression and activation in antineutrophil cytoplasmatic antibody-associated crescentic glomerulonephritis: Role of p38MAPKα. Ann. Rheum. Dis. 67, 602-608 (2008). (Pubitemid 351571921)
122. Pengal, R. et al. Inhibition of the protein kinase MK 2 protects podocytes from nephrotic syndrome-related injury. Am. J. Physiol. Renal Physiol. 301, F509-F519 (2011).
123. Yoshida, S., Nagase, M., Shibata, S. & Fujita, T. Podocyte injury induced by albumin overload in vivo and in vitro: Involvement of TGF-β and p38 MAPK. Nephron Exp. Nephrol. 108, e57-e68 (2008). (Pubitemid 351592585)
124. Sekar, M. C., Yang, M., Meezan, E. & Pillion, D. J. Angiotensin II and bradykinin stimulate phosphoinositide breakdown in intact rat kidney glomeruli but not in proximal tubules: Glomerular response modulated by phorbol ester. Biochem. Biophys. Res. Commun. 166, 373-379 (1990). (Pubitemid 20040196)
125. Nowicki, S., Kruse, M. S., Brismar, H. & Aperia, A. Dopamine-induced translocation of protein kinase C isoforms visualized in renal epithelial cells. Am. J. Physiol. Cell. Physiol. 279, C1812-C1818 (2000).
126. Huber, T. B. et al. Loss of podocyte aPKC?/? causes polarity defects and nephrotic syndrome. J. Am. Soc. Nephrol. 20, 798-806 (2009).
127. Menne, J. et al. Diminished loss of proteoglycans and lack of albuminuria in protein kinase C α deficient diabetic mice. Diabetes 53, 2101-2109 (2004). (Pubitemid 38970761)
128. Tossidou, I. et al. PKC-α modulates TGF-β signaling and impairs podocyte survival. Cell. Physiol. Biochem. 24, 627-634 (2009).
129. Schiffer, M. et al. Apoptosis in podocytes induced by TGF-β and Smad7. J. Clin. Invest. 108, 807-816 (2001). (Pubitemid 32880291)
130. Shen, G. X. Selective protein kinase C inhibitors and their applications. Curr. Drug Targets Cardiovasc. Haematol. Disord. 3, 301-307 (2003). (Pubitemid 37540861)
131. Gaestel, M., Mengel, A., Bothe, U. & Asadullah, K. Protein kinases as small molecule inhibitor targets in inflammation. Curr. Med. Chem. 14, 2214-2234 (2007). (Pubitemid 47570683)
132. Baier, G. & Wagner, J. PKC inhibitors: Potential in T cell-dependent immune diseases. Curr. Opin. Cell. Biol. 21, 262-267 (2009).
133. Wagner, E. F. & Nebreda, A. R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 9, 537-549 (2009).
134. Yong, H. Y., Koh, M. S. & Moon, A. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin. Investig. Drugs 18, 1893-1905 (2009).
135. Roffey, J. et al. Protein kinase C intervention: The state of play. Curr. Opin. Cell. Biol. 21, 268-279 (2009).
136. Niranjan, T., Murea, M. & Susztak, K. The pathogenic role of Notch activation in podocytes. Nephron Exp. Nephrol. 111, e73-e79 (2009).
137. Barisoni, L. Notch signaling: A common pathway of injury in podocytopathies? J. Am. Soc. Nephrol. 19, 1045-1046 (2008).
138. Niranjan, T. et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat. Med. 14, 290-298 (2008). (Pubitemid 351347919)
139. Walsh, D. W. et al. Co-regulation of Gremlin and Notch signalling in diabetic nephropathy. Biochim. Biophys. Acta 1782, 10-21 (2008).
140. Waters, A. M. et al. Ectopic notch activation in developing podocytes causes glomerulosclerosis. J. Am. Soc. Nephrol. 19, 1139-1157 (2008).
141. Lasagni, L. et al. Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders. Stem Cells 28, 1674-1685 (2010).
142. Sharma, S., Sirin, Y. & Susztak, K. The story of Notch and chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 20, 56-61 (2011).
143. Purow, B. Notch inhibition as a promising new approach to cancer therapy. Adv. Exp. Med. Biol. 727, 305-319 (2012).
144. Araya, C. et al. T regulatory cell function in idiopathic minimal lesion nephrotic syndrome. Pediatr. Nephrol. 3, 3 (2009).
145. Assadi, F. Neonatal nephrotic syndrome associated with placental transmission of proinflammatory cytokines. Pediatr. Nephrol. 26, 469-471 (2011).
146. Jiang, H. K., Luo, G. & Jiang, H. Interleukin 18 expression in peripheral blood mononuclear cells in children with steroid-resistant nephrotic syndrome [Chinese]. Zhongguo Dang Dai Er Ke Za Zhi 11, 337-340 (2009).
147. Kanai, T. et al. Elevated serum interleukin 7 level in idiopathic steroid-sensitive nephrotic syndrome. Pediatr. Int. 53, 906-909 (2011).
148. Souto, M. F. et al. Immune mediators in idiopathic nephrotic syndrome: Evidence for a relation between interleukin 8 and proteinuria. Pediatr. Res. 64, 637-642 (2008).
149. Van Den Berg, J. G. & Weening, J. J. Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome. Clin. Sci. 107, 125-136 (2004). (Pubitemid 39070928)
150. Yap, H. K. et al. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: Evidence for increased IL 13 mRNA expression in relapse. J. Am. Soc. Nephrol. 10, 529-537 (1999).
151. Jiang, H. K., Jiang, H., Luo, G. & Sun, G. L. Interleukin 13 expression before and after pulse treatment with methylprednisolone in children with steroid-responsive nephrotic syndrome [Chinese]. Zhongguo Dang Dai Er Ke Za Zhi 9, 533-536 (2007).
152. Tain, Y. L., Chen, T. Y. & Yang, K. D. Implications of serum TNF-β and IL 13 in the treatment response of childhood nephrotic syndrome. Cytokine 21, 155-159 (2003). (Pubitemid 36407718)
153. Lai, K. W. et al. Overexpression of interleukin 13 induces minimal change like nephropathy in rats. J. Am. Soc. Nephrol. 18, 1476-1485 (2007).
154. Corren, J. et al. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365, 1088-1098 (2011).
155. Chakrabarti, A., Chen, A. W. & Varner, J. D. A review of the mammalian unfolded protein response. Biotechnol. Bioeng. 108, 2777-2793 (2011).
156. Markan, S. et al. Up regulation of the GRP 78 and GADD 153 and down regulation of Bcl 2 proteins in primary glomerular diseases: A possible involvement of the ER stress pathway in glomerulonephritis. Mol. Cell. Biochem. 324, 131-138 (2009).
157. Ito, N. et al. mTORC1 activation triggers the unfolded protein response in podocytes and leads to nephrotic syndrome. Lab. Invest. 91, 1584-1595 (2011).
158. Cybulsky, A. V. et al. Complement C5b 9 membrane attack complex increases expression of endoplasmic reticulum stress proteins in glomerular epithelial cells. J. Biol. Chem. 277, 41342-41351 (2002). (Pubitemid 35257434)
159. Kitamura, M. Endoplasmic reticulum stress and unfolded protein response in renal pathophysiology: Janus faces. Am. J. Physiol. Renal Physiol. 295, F323-F334 (2008).
160. Henderson, J. M., Alexander, M. P. & Pollak, M. R. Patients with ACTN4 mutations demonstrate distinctive features of glomerular injury. J. Am. Soc. Nephrol. 20, 961-968 (2009).
161. Cybulsky, A. V. & Kennedy, C. R. Podocyte injury associated with mutant α actinin 4. J. Signal Transduct. 2011, 563128 (2011).
162. Liu, X. L. et al. Defective trafficking of nephrin missense mutants rescued by a chemical chaperone. J. Am. Soc. Nephrol. 15, 1731-1738 (2004). (Pubitemid 38822051)
163. Ehrnhoefer, D. E. et al. Green tea ( ) epigallocatechin gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntingtons disease models. Hum. Mol. Genet. 15, 2743-2751 (2006). (Pubitemid 44400401)
164. Mishra, O. P. et al. Antioxidant status of children with idiopathic nephrotic syndrome. Pediatr. Nephrol. 26, 251-256 (2011).
165. Pavlova, E. L., Lilova, M. I. & Savov, V. M. Oxidative stress in children with kidney disease. Pediatr. Nephrol. 20, 1599-1604 (2005). (Pubitemid 41554473)
166. Kamireddy, R. et al. Oxidative stress in pediatric nephrotic syndrome. Clin. Chim. Acta 325, 147-150 (2002). (Pubitemid 35279637)
167. Ece, A. et al. Paraoxonase, total antioxidant response, and peroxide levels in children with steroid-sensitive nephrotic syndrome. Pediatr. Nephrol. 20, 1279-1284 (2005). (Pubitemid 41222975)
168. Ghodake, S. R. et al. Role of free radicals and antioxidant status in childhood nephrotic syndrome. Indian J. Nephrol. 21, 37-40 (2011).
169. Agardh, C. D., Stenram, U., Torffvit, O. & Agardh, E. Effects of inhibition of glycation and oxidative stress on the development of diabetic nephropathy in rats. J. Diabetes Complications 16, 395-400 (2002). (Pubitemid 35449085)
170. Sawant, S. U., Chandran, S., Almeida, A. F. & Rajan, M. G. Correlation between oxidative stress and thyroid function in patients with nephrotic syndrome. Int. J. Nephrol. 2011, 256420 (2011).
171. Duann, P. et al. Superoxide dismutase mimetic preserves the glomerular capillary permeability barrier to protein. J. Pharmacol. Exp. Ther. 316, 1249-1254 (2006). (Pubitemid 43345300)
172. Nakakura, H., Ashida, A., Hirano, K. & Tamai, H. Oxidative stress in a rat model of nephrosis can be quantified by electron spin resonance. Pediatr. Nephrol. 19, 266-270 (2004). (Pubitemid 38313008)
173. Marshall, C. B., Pippin, J. W., Krofft, R. D. & Shankland, S. J. Puromycin aminonucleoside induces oxidant-dependent DNA damage in podocytes in vitro and in vivo. Kidney Int. 70, 1962-1973 (2006). (Pubitemid 44863385)
174. Vega-Warner, V., Ransom, R. F., Vincent, A. M., Brosius, F. C. & Smoyer, W. E. Induction of antioxidant enzymes in murine podocytes precedes injury by puromycin aminonucleoside. Kidney Int. 66, 1881-1889 (2004). (Pubitemid 41094312)
175. Kinugasa, S. et al. Selective albuminuria via podocyte albumin transport in puromycin nephrotic rats is attenuated by an inhibitor of NADPH oxidase. Kidney Int. 80, 1328-1338 (2011).
176. Alvarez, B., Carballal, S., Turell, L. & Radi, R. Formation and reactions of sulfenic acid in human serum albumin. Methods Enzymol. 473, 117-136 (2010).
177. Candiano, G. et al. The oxido-redox potential of albumin methodological approach and relevance to human diseases. J. Proteomics 73, 188-195 (2009).
178. Bruschi, M. et al. Analysis of the oxido-redox status of plasma proteins. Technology advances for clinical applications. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 879, 1338-1344 (2011).
179. Lee, H. S. et al. Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. Kidney Int. 51, 1151-1159 (1997). (Pubitemid 27186541)
180. Matsumura, H., Ashida, A., Hirano, K., Nakakura, H. & Tamai, H. Protective effect of radical scavenger edaravone against puromycin nephrosis. Clin. Nephrol. 66, 405-410 (2006). (Pubitemid 44896148)
181. Tahzib, M., Frank, R., Gauthier, B., Valderrama, E. & Trachtman, H. Vitamin E treatment of focal segmental glomerulosclerosis: Results of an open-label study. Pediatr. Nephrol. 13, 649-652 (1999). (Pubitemid 29438443)
182. Kestilä, M. et al. Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol. Cell 1, 575-582 (1998). (Pubitemid 128374693)
183. Chiang, C. K. & Inagi, R. Glomerular diseases: Genetic causes and future therapeutics. Nat. Rev. Nephrol. 6, 539-554 (2010).
184. McCarthy, H. J. & Saleem, M. A. Genetics in clinical practice: Nephrotic and proteinuric syndromes. Nephron Exp. Nephrol. 118, e1-e8 (2011).
185. Pei, Y. INF2 is another piece of the jigsaw puzzle for FSGS. J. Am. Soc. Nephrol. 22, 197-199 (2011).
186. Akilesh, S. et al. Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. J. Clin. Invest. 121, 4127-4137 (2011).
187. Hasselbacher, K. et al. Recessive missense mutations in LAMB2 expand the clinical spectrum of LAMB2-associated disorders. Kidney Int. 70, 1008-1012 (2006). (Pubitemid 44344069)
188. Santin, S. et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 6, 1139-1148 (2011).
189. Hinkes, B. G. et al. Nephrotic syndrome in the first year of life: Two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics 119, e907-e919 (2007). (Pubitemid 46556655)
190. Schlondorff, J., Del Camino, D., Carrasquillo, R., Lacey, V. & Pollak, M. R. TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription. Am. J. Physiol. Cell. Physiol. 296, C558-C569 (2009).
191. Dryer, S. E. & Reiser, J. TRPC6 channels and their binding partners in podocytes: Role in glomerular filtration and pathophysiology. Am. J. Physiol. Renal Physiol. 299, F689-F701 (2010).
192. Bensman, A. & Niaudet, P. Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies. Pediatr. Nephrol. 25, 1197-1199 (2010).
193. Nijenhuis, T. et al. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am. J. Pathol. 179, 1719-1732 (2011).
194. Gipson, D. S. et al. Differential risk of remission and ESRD in childhood FSGS. Pediatr. Nephrol. 21, 344-349 (2006). (Pubitemid 43280349)
195. Redmond, E. M., Guha, S., Walls, D. & Cahill, P. A. Investigational Notch and Hedgehog inhibitors-therapies for cardiovascular disease. Expert Opin. Investig. Drugs 20, 1649-1664 (2011).
196. Woolf, A. S. & Pitera, J. E. in Pediatric Nephrology (eds Avner, E. D., Harmon, W. E., Niaudet, P. & Yoshikawa, N.) 3-3 (Lippincott Williams & Wilkins, Philadelphia, 2009).
197. Kopan, R., Cheng, H. T. & Surendran, K. Molecular insights into segmentation along the proximal-distal axis of the nephron. J. Am. Soc. Nephrol. 18, 2014-2020 (2007). (Pubitemid 47041065)
198. Chen, L. & Al-Awqati, Q. Segmental expression of Notch and Hairy genes in nephrogenesis. Am. J. Physiol. Renal Physiol. 288, F939-F952 (2005). (Pubitemid 40569760)
199. McCright, B. et al. Defects in development of the kidney, heart and eye vasculature in mice homozygous for a hypomorphic Notch2 mutation. Development 128, 491-502 (2001). (Pubitemid 32229592)
200. Cheng, H. T. et al. Notch2, but not Notch1, is required for proximal fate acquisition in the mammalian nephron. Development 134, 801-811 (2007).
201. Cheng, H. T. & Kopan, R. The role of Notch signaling in specification of podocyte and proximal tubules within the developing mouse kidney. Kidney Int. 68, 1951-1952 (2005).(Pubitemid 43117769)